CARA - Cara Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Stamford,
United States
Type: Equity
CARA price evolution
CARA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.24 | $47 | $52.18 | |
| Short term investments | $7.38 | $22.78 | $48.98 | |
| Net receivables | $1.37 | $1.12 | $2.22 | $3.32 |
| Inventory | $0.63 | $1.64 | $2.74 | $2.82 |
| Total current assets | $47.91 | $63.86 | $81.22 | $116.16 |
| Long term investments | $1.5 | $1.5 | $1.5 | |
| Property, plant & equipment | $3.42 | $7.14 | $7.37 | $8.19 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8.64 | $8.87 | $9.69 | |
| Total investments | $8.88 | $24.28 | $50.48 | |
| Total assets | $51.33 | $72.5 | $90.1 | $125.84 |
| Current liabilities | ||||
| Accounts payable | $2.54 | $13.73 | $14.88 | $25.59 |
| Deferred revenue | ||||
| Short long term debt | $0.17 | $0.22 | ||
| Total current liabilities | $10.04 | $13.9 | $15.1 | $25.59 |
| Long term debt | $47 | $45.2 | $43.17 | |
| Total noncurrent liabilities | $47 | $45.2 | $43.17 | |
| Total debt | $47.16 | $45.42 | $43.17 | |
| Total liabilities | $50.62 | $60.9 | $60.3 | $68.76 |
| Shareholders' equity | ||||
| Retained earnings | -$747.93 | -$735.46 | -$715.44 | -$684.75 |
| Other shareholder equity | -$0.03 | -$0.12 | -$0.19 | -$0.26 |
| Total shareholder equity | $11.6 | $29.8 | $57.09 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.18 | $64.15 | $13.86 | $32.09 |
| Short term investments | $48.98 | $81.66 | $153.58 | $149.24 |
| Net receivables | $3.32 | $4.45 | $0.46 | $0.56 |
| Inventory | $2.82 | $2.38 | $2.58 | |
| Total current assets | $116.16 | $168.91 | $173.29 | $195.06 |
| Long term investments | $1.5 | $11.35 | $69.75 | $70.56 |
| Property, plant & equipment | $8.19 | $1.98 | $3.6 | $5.12 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.69 | $13.33 | $73.77 | $76.09 |
| Total investments | $50.48 | $93.01 | $223.34 | $219.81 |
| Total assets | $125.84 | $182.24 | $247.06 | $271.16 |
| Current liabilities | ||||
| Accounts payable | $25.59 | $9.6 | $15.86 | $16.88 |
| Deferred revenue | ||||
| Short long term debt | $1.92 | $1.75 | $1.6 | |
| Total current liabilities | $25.59 | $23.46 | $17.62 | $18.48 |
| Long term debt | $43.17 | $1.92 | $3.67 | |
| Total noncurrent liabilities | $43.17 | $1.92 | $3.67 | |
| Total debt | $43.17 | $1.92 | $3.67 | $5.28 |
| Total liabilities | $68.76 | $23.46 | $19.53 | $22.16 |
| Shareholders' equity | ||||
| Retained earnings | -$684.75 | -$566.23 | -$480.76 | -$392.32 |
| Other shareholder equity | -$0.26 | -$1.67 | -$0.36 | $0.07 |
| Total shareholder equity | $57.09 | $158.78 | $227.52 | $249 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.99 | $2.13 | $3 | |
| Cost of revenue | $0.62 | $0.61 | ||
| Gross Profit | $0.99 | $1.51 | $2.4 | |
| Operating activities | ||||
| Research & development | $9.31 | $21.96 | $28.41 | |
| Selling, general & administrative | $6.41 | $6.82 | $6.59 | |
| Total operating expenses | $19.79 | $31.18 | $35 | |
| Operating income | -$18.8 | -$29.67 | -$32.61 | |
| Income from continuing operations | ||||
| EBIT | -$18.11 | -$28.71 | -$31.73 | |
| Income tax expense | ||||
| Interest expense | $1.91 | $1.98 | $0.6 | |
| Net income | ||||
| Net income | -$20.02 | -$30.7 | -$32.34 | |
| Income (for common shares) | -$20.02 | -$30.7 | -$32.34 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $20.97 | $41.87 | $23.03 | $135.08 |
| Cost of revenue | $6.17 | $7.27 | ||
| Gross Profit | $14.79 | $34.6 | $23.03 | $135.08 |
| Operating activities | ||||
| Research & development | $108.51 | $91.88 | $82.7 | $107.85 |
| Selling, general & administrative | $27.78 | $30.26 | $29.41 | $21.85 |
| Total operating expenses | $136.29 | $122.14 | $112.11 | $129.7 |
| Operating income | -$121.5 | -$87.53 | -$89.08 | $5.38 |
| Income from continuing operations | ||||
| EBIT | -$117.91 | -$85.47 | -$88.44 | $7.72 |
| Income tax expense | -$0.69 | |||
| Interest expense | $0.6 | |||
| Net income | ||||
| Net income | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| Income (for common shares) | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$20.02 | -$30.7 | -$32.34 | |
| Operating activities | ||||
| Depreciation | $0.33 | $0.31 | $0.94 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.74 | $3.35 | $3.6 | |
| Total cash flows from operations | -$12.44 | -$30.45 | -$17.37 | |
| Investing activities | ||||
| Capital expenditures | -$0.21 | -$0.84 | -$2.05 | |
| Investments | $15.5 | $26.79 | -$28.15 | |
| Total cash flows from investing | $43.74 | $15.29 | $25.95 | -$30.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | |||
| Net borrowings | -$0.61 | -$0.69 | $36.47 | |
| Total cash flows from financing | -$1.99 | -$0.61 | -$0.69 | $36.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.12 | $2.24 | -$5.19 | -$11.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| Operating activities | ||||
| Depreciation | $2.33 | $1.67 | $1.55 | $1.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.73 | $17.73 | $20.79 | $14.84 |
| Total cash flows from operations | -$92.08 | -$78.73 | -$60.09 | -$5.49 |
| Investing activities | ||||
| Capital expenditures | -$2.38 | -$0.04 | $0.03 | -$0.35 |
| Investments | $45.84 | $128.75 | -$4.78 | -$19.93 |
| Total cash flows from investing | $43.46 | $128.71 | -$4.75 | -$20.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.68 | $0.31 | $46.61 | $39.14 |
| Net borrowings | $36.47 | |||
| Total cash flows from financing | $38.15 | $0.31 | $46.61 | $39.14 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.47 | $50.29 | -$18.23 | $13.38 |
News
Fundamentals
| Market cap | $23.20M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 54.85M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.77 |
| Quick ratio | 4.71 |